Table 1.
Baseline patient characteristics
| Characteristics | FOLFIRI plus panitumumab (n = 59) | FOLFIRI plus bevacizumab (n = 58) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Age, years | ||||
| Median, range | 62 | 31–82 | 64 | 26–78 |
| Age, years | ||||
| <65 | 34 | 57.6 | 29 | 50.0 |
| 65 or more | 25 | 42.4 | 29 | 50.0 |
| Gender | ||||
| Male | 34 | 57.6 | 39 | 67.2 |
| Female | 25 | 42.4 | 19 | 32.8 |
| ECOG PS | ||||
| 0 | 47 | 79.7 | 43 | 74.1 |
| 1 | 12 | 20.3 | 15 | 25.9 |
| Köhne index | ||||
| Low | 23 | 39.0 | 25 | 43.1 |
| Intermediate | 14 | 23.7 | 13 | 22.4 |
| High | 22 | 37.3 | 20 | 34.5 |
| Prior surgery | ||||
| Yes | 49 | 83.1 | 47 | 81.0 |
| Prior adjuvant treatment | ||||
| Yes | 16 | 27.1 | 15 | 25.9 |
| Prior first‐line treatment | ||||
| FOLFOX + bevacizumab | 45 | 76.3 | 45 | 77.6 |
| CapeOX + bevacizumab | 14 | 23.7 | 12 | 20.7 |
| SOX + bevacizumab | 0 | 0 | 1 | 1.7 |
| Duration of first‐line | ||||
| 6 months or more | 50 | 84.7 | 49 | 84.5 |
| Measurable lesion | ||||
| Present | 52 | 88.1 | 53 | 91.4 |
| Metastatic sites | ||||
| Liver | 35 | 59.3 | 39 | 67.2 |
| Lung | 31 | 52.5 | 28 | 48.3 |
| Lymph node | 24 | 40.7 | 21 | 36.2 |
| No. of metastatic sites | ||||
| 1 | 22 | 37.3 | 20 | 34.5 |
| 2 or more | 37 | 62.7 | 38 | 65.5 |
CapeOX, capecitabine plus oxaliplatin; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX, combination of fluorouracil, leucovorin, and oxaliplatin; SOX, S1 plus oxaliplatin.